Coherus Aims To Pull Out $75m In Costs Amid Conservative 2023 Guidance
Three Launches Eyed Next Year, Alongside Recent Ranibizumab Biosimilar
Coherus BioSciences saw its Q3 revenues tumble by 45% as it arrived at the firm’s projected nadir. A swathe of launches and a cost-cutting program are targeted to bring the firm back to profitability in 2024.
